BR112014009322A2 - inibidor de catecol-o-metiltransferase (comt), combinação do mesmo com um agente terapêutico adicional e agente terapêutico - Google Patents
inibidor de catecol-o-metiltransferase (comt), combinação do mesmo com um agente terapêutico adicional e agente terapêuticoInfo
- Publication number
- BR112014009322A2 BR112014009322A2 BR112014009322A BR112014009322A BR112014009322A2 BR 112014009322 A2 BR112014009322 A2 BR 112014009322A2 BR 112014009322 A BR112014009322 A BR 112014009322A BR 112014009322 A BR112014009322 A BR 112014009322A BR 112014009322 A2 BR112014009322 A2 BR 112014009322A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic agent
- comt
- methyltransferase
- catechol
- inhibitor
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 2
- 229940124597 therapeutic agent Drugs 0.000 title 2
- 101150106671 COMT gene Proteins 0.000 title 1
- 102000006378 Catechol O-methyltransferase Human genes 0.000 title 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11382326.4 | 2011-10-24 | ||
EP11382326 | 2011-10-24 | ||
PCT/EP2012/070945 WO2013060668A1 (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014009322A2 true BR112014009322A2 (pt) | 2017-04-18 |
BR112014009322A8 BR112014009322A8 (pt) | 2018-01-16 |
BR112014009322B1 BR112014009322B1 (pt) | 2022-05-10 |
Family
ID=47076222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014009322-9A BR112014009322B1 (pt) | 2011-10-24 | 2012-10-23 | Uso de um inibidor de catecol-o-metiltransferase (comt) |
Country Status (20)
Country | Link |
---|---|
US (5) | US9610270B2 (pt) |
EP (1) | EP2770988B1 (pt) |
JP (1) | JP6068484B2 (pt) |
KR (1) | KR102017354B1 (pt) |
CN (1) | CN103889407B (pt) |
AU (2) | AU2012327275B2 (pt) |
BR (1) | BR112014009322B1 (pt) |
CA (1) | CA2852808C (pt) |
CL (1) | CL2014000893A1 (pt) |
CY (1) | CY1118151T1 (pt) |
ES (1) | ES2593038T3 (pt) |
HK (1) | HK1198432A1 (pt) |
IL (1) | IL231907B (pt) |
MX (1) | MX347784B (pt) |
PL (1) | PL2770988T3 (pt) |
PT (1) | PT2770988T (pt) |
RU (2) | RU2747536C2 (pt) |
SG (2) | SG11201401215VA (pt) |
WO (1) | WO2013060668A1 (pt) |
ZA (1) | ZA201402546B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2747536C2 (ru) * | 2011-10-24 | 2021-05-06 | Сом Инновэйшн Биотек, С.Л. | Новая терапия транстиретин-ассоциированного амилоидоза |
KR102631505B1 (ko) * | 2014-08-29 | 2024-02-01 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법 |
EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
GB2585792A (en) * | 2018-03-12 | 2021-01-20 | Corino Therapeutics Inc | Combination of therapy for TTR amyloidosis |
MX2021014682A (es) * | 2019-05-31 | 2022-04-06 | Plex Pharmaceuticals Inc | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. |
CN114324693B (zh) * | 2022-01-14 | 2023-01-13 | 大连博源医学科技有限公司 | 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
AU5727798A (en) | 1996-12-23 | 1998-07-17 | Texas A & M University, The | Anti-amyloidogenic agents |
FI20002044A0 (fi) * | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
EP1372682B1 (en) | 2001-03-15 | 2012-05-02 | Proteotech Inc. | Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
AU2003303666A1 (en) | 2002-01-29 | 2004-08-13 | Protemix Discovery Limited | Suppression of cytotoxic protein conformers |
US20040175382A1 (en) | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
CA2555399A1 (en) | 2004-02-20 | 2005-09-01 | Novartis Ag | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
CN1921856A (zh) * | 2004-02-20 | 2007-02-28 | 诺瓦提斯公司 | 用于治疗神经变性疾病和认知障碍的dpp-iv抑制剂 |
EP1768968A1 (en) | 2004-05-20 | 2007-04-04 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
DE602005019582D1 (de) | 2004-08-30 | 2010-04-08 | Seo Hong Yoo | Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell |
GB2429645A (en) | 2006-03-10 | 2007-03-07 | Sekhsaria Chemicals Ltd | Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent |
US20120016037A1 (en) | 2006-07-24 | 2012-01-19 | Frank Toppo | Method for prevention and treatment of Alzheimers |
GB0718718D0 (en) | 2007-09-25 | 2007-11-07 | Pentraxin Therapeutics Ltd | Compound and use thereof |
DE102010010572A1 (de) | 2010-03-08 | 2011-09-08 | Mahle International Gmbh | Trockenseparator |
RU2747536C2 (ru) * | 2011-10-24 | 2021-05-06 | Сом Инновэйшн Биотек, С.Л. | Новая терапия транстиретин-ассоциированного амилоидоза |
-
2012
- 2012-10-23 RU RU2017119539A patent/RU2747536C2/ru active
- 2012-10-23 KR KR1020147010767A patent/KR102017354B1/ko active IP Right Grant
- 2012-10-23 SG SG11201401215VA patent/SG11201401215VA/en unknown
- 2012-10-23 WO PCT/EP2012/070945 patent/WO2013060668A1/en active Application Filing
- 2012-10-23 AU AU2012327275A patent/AU2012327275B2/en active Active
- 2012-10-23 JP JP2014536290A patent/JP6068484B2/ja active Active
- 2012-10-23 PL PL12778323T patent/PL2770988T3/pl unknown
- 2012-10-23 PT PT127783231T patent/PT2770988T/pt unknown
- 2012-10-23 CA CA2852808A patent/CA2852808C/en active Active
- 2012-10-23 EP EP12778323.1A patent/EP2770988B1/en active Active
- 2012-10-23 BR BR112014009322-9A patent/BR112014009322B1/pt active IP Right Grant
- 2012-10-23 CN CN201280051812.8A patent/CN103889407B/zh active Active
- 2012-10-23 ES ES12778323.1T patent/ES2593038T3/es active Active
- 2012-10-23 SG SG10201609933WA patent/SG10201609933WA/en unknown
- 2012-10-23 US US14/353,459 patent/US9610270B2/en active Active
- 2012-10-23 RU RU2014114930A patent/RU2623062C2/ru active
- 2012-10-23 MX MX2014004863A patent/MX347784B/es active IP Right Grant
-
2014
- 2014-04-03 IL IL231907A patent/IL231907B/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02546A patent/ZA201402546B/en unknown
- 2014-04-09 CL CL2014000893A patent/CL2014000893A1/es unknown
- 2014-11-26 HK HK14111954.5A patent/HK1198432A1/xx unknown
-
2016
- 2016-09-20 CY CY20161100934T patent/CY1118151T1/el unknown
-
2017
- 2017-03-02 US US15/448,054 patent/US10045956B2/en active Active
- 2017-04-21 AU AU2017202670A patent/AU2017202670B2/en active Active
-
2018
- 2018-08-13 US US16/101,882 patent/US10449169B2/en active Active
-
2019
- 2019-09-12 US US16/569,055 patent/US10786473B2/en active Active
-
2020
- 2020-08-28 US US17/005,893 patent/US11564899B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ME03347B (me) | PARAZITICIDNE KOMPOZICIJE KOJE SADRŽE IZOKSAZOLINSKO AKTIVNO SREDSTVO, POSTUPCI l UPOTREBE POVEZANE SA NJIMA | |
BR112015001838A2 (pt) | composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo. | |
BR112014009634A2 (pt) | preparação e agente terapêutico | |
BR112013013311A2 (pt) | agente terapêutico de indução de citotoxicidade | |
IL238958B (en) | Glutaminase inhibitors, preparations containing them and their uses | |
IT1400425B1 (it) | Modified snrnas for use in therapy. | |
BR112013031361A2 (pt) | galactomanana cationicamente e anfifilicamente modificada, e, composição | |
IL245839B (en) | Inhibitors of rna polymerase i and use of preparations containing them for treatment | |
EP3022320A4 (en) | Whole-genome and targeted haplotype reconstruction | |
BR112014009322A8 (pt) | inibidor de catecol-o-metiltransferase (comt), combinação do mesmo com um agente terapêutico adicional e agente terapêutico | |
HK1212254A1 (en) | Treatments for depression and other diseases with a low dose agent | |
BR112014010288A2 (pt) | métodos, composição e aparelho refrigerador | |
BR112013009711A2 (pt) | agente reticulante | |
DK2877736T3 (da) | Skrue, skruedel og fremgangsmåde dertil | |
BR112014007243A2 (pt) | composição, componentes e dispositivo de iluminação | |
BR112015014386A2 (pt) | dispositivo de distribuição de agente intramiocárdico e métodos relacionados | |
BR112014017217A2 (pt) | agente e composição farmacêutica | |
DK2900234T3 (da) | Kræft-kemoterapeutisk middel/formulering, fremstilling og anvendelse deraf | |
IT1400480B1 (it) | Pomata per bruciature e procedimento per il suo ottenimento. | |
TH131704B (th) | ตัวต่อที่มีกลไกที่ใช้ล็อคและระบบและวิธีการที่เกี่ยวเนื่อง |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2012, OBSERVADAS AS CONDICOES LEGAIS |